Literature DB >> 15142112

Interstitial pneumonitis during imatinib therapy.

Ikuko Isshiki1, Kazuhiro Yamaguchi, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15142112     DOI： 10.1111/j.1365-2141.2004.04833.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  Pulmonary toxicities from targeted therapies: a review.

Authors:  Nicholas A Barber; Apar Kishor Ganti
Journal:  Target Oncol       Date:  2011-11-11       Impact factor: 4.493

2.  Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib.

Authors:  Nabeel Salmons; Richard J Gregg; Anna Pallalau; Ian Woolhouse; Ian Geh; Philippe Tanière
Journal:  J Clin Pathol       Date:  2007-02       Impact factor: 3.411

3.  Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.

Authors:  Philipp Ivanyi; Thomas Winkler; Anika Grosshennig; Christoph Reuter; Axel S Merseburger; Arnold Ganser; Viktor Grünwald
Journal:  World J Urol       Date:  2010-05-05       Impact factor: 4.226

Review 4.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

5.  Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.

Authors:  Kirsi Vuorinen; Fei Gao; Tim D Oury; Vuokko L Kinnula; Marjukka Myllärniemi
Journal:  Exp Lung Res       Date:  2007-09       Impact factor: 2.459

6.  Interstitial pneumonitis in a patient with chronic myeloid leukemia.

Authors:  Ahmet Emre Eşkazan; Ayşe Salihoğlu; Serdar Erturan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

7.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.